4 news items
Galapagos Q1 EPS €1.40 Vs €0.40 YoY; Revenue €62.4 Million Vs €58.6 Million YoY
GLPG
2 May 24
revenues are booked in total net revenues.R&D expenses in the first three months of 2024 amounted to €71.6 million
Galapagos reports first quarter 2024 financial results
GLPG
2 May 24
potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery
Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline
GLPG
22 Feb 24
platform and a pipeline of potential best-in-class assets that fit with Galapagos' precision oncology R&D approach. The participation in Frontier
Galapagos announces full year 2023 results and outlook for 2024
GLPG
22 Feb 24
of potential best-in-class assets that fit with Galapagos' precision oncology R&D approach. The investment aligns with our innovation acceleration
- Prev
- 1
- Next